Corrigendum: Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation

Frontiers in Endocrinology

Endocrinology

Yutaka Takahashi¹  Jens Otto L. Jørgensen²  Hiroshi Nishioka³  David Clemmons⁴  Martin Bidlingmaier⁵  Beverly M.K. Biller⁶ 

[1] Department of Diabetes and Endocrinology, Nara Medical University, Kashihara, Japan;Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan;Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark;Department of Hypothalamic and Pituitary Surgery, Toranomon Hospital, Tokyo, Japan;Department of Medicine, University of North Carolina, Chapel Hill, NC, United States;Endocrine Laboratory, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany;Neuroendocrine & Pituitary Tumor Clinical Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States;

关键词: somapacitan;    growth hormone;    adult growth hormone deficiency;    insulin-like growth factor I;    treatment recommendations;    pharmacokinetic/pharmacodynamic modelling;    long-acting growth hormone;   

DOI  :  10.3389/fendo.2023.1158214

 received in 2023-02-03, accepted in 2023-02-06,  发布年份 2023

来源: Frontiers

【 授权许可】

Unknown   
Copyright © 2023 Bidlingmaier, Biller, Clemmons, Jørgensen, Nishioka and Takahashi